Home
/
Crinetics Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Crinetics Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Crinetics Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2025
Jun 30, 2025
$1.03M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$361.0K
May 8, 2025
Q2
2025
Jun 30, 2024
$399.0K
Aug 7, 2025
Q1
2025
Mar 31, 2024
$640.0K
May 8, 2025
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$143.0K
Nov 6, 2025
Q2
2025
Jun 30, 2025
$1.03M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$361.0K
May 8, 2025
Q3
2025
Sep 30, 2024
$0
Nov 6, 2025
Q2
2025
Jun 30, 2024
$399.0K
Aug 7, 2025
Q1
2025
Mar 31, 2024
$640.0K
May 8, 2025
Q3
2024
Sep 30, 2023
$346.0K
Nov 12, 2024
Q2
2024
Jun 30, 2023
$988.0K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$2.68M
May 9, 2024
Q3
2023
Sep 30, 2022
$458.0K
Nov 7, 2023
Q2
2023
Jun 30, 2022
$439.0K
Aug 8, 2023
Q1
2023
Mar 31, 2022
$3.13M
May 9, 2023
Q3
2022
Sep 30, 2021
$0
Nov 14, 2022
Q1
2022
Mar 31, 2021
$0
May 12, 2022
Q3
2021
Sep 30, 2020
$71.0K
Nov 5, 2021
Q2
2021
Jun 30, 2020
$71.0K
Aug 10, 2021
Q1
2021
Mar 31, 2020
$71.0K
May 6, 2021
Q3
2020
Sep 30, 2019
$505.0K
Nov 6, 2020
Q2
2020
Jun 30, 2019
$367.0K
Aug 7, 2020
Q1
2020
Mar 31, 2019
$367.0K
May 8, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($130.09M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($115.64M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($96.77M)
May 8, 2025
Q3
2025
Sep 30, 2024
($76.83M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($74.06M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($66.93M)
May 8, 2025
Q3
2024
Sep 30, 2023
($57.46M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($50.98M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($46.00M)
May 9, 2024
Q3
2023
Sep 30, 2022
($41.93M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($42.38M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($34.63M)
May 9, 2023
Q3
2022
Sep 30, 2021
($27.85M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($26.10M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($22.90M)
May 12, 2022
Q3
2021
Sep 30, 2020
($18.32M)
Nov 5, 2021
Q2
2021
Jun 30, 2020
($16.49M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($17.36M)
May 6, 2021
Q3
2020
Sep 30, 2019
($14.43M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($12.43M)
Aug 7, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($142.59M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($129.11M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($111.41M)
May 8, 2025
Q3
2025
Sep 30, 2024
($87.80M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($82.78M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($73.53M)
May 8, 2025
Q3
2024
Sep 30, 2023
($58.98M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($53.00M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($47.98M)
May 9, 2024
Q3
2023
Sep 30, 2022
($43.45M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($43.05M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($33.83M)
May 9, 2023
Q3
2022
Sep 30, 2021
($27.81M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($26.09M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($22.92M)
May 12, 2022
Q3
2021
Sep 30, 2020
($18.45M)
Nov 5, 2021
Q2
2021
Jun 30, 2020
($16.93M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($17.78M)
May 6, 2021
Q3
2020
Sep 30, 2019
($15.23M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($13.35M)
Aug 7, 2020